Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 3/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.33 |
| ▸ | PARP11 | Q9NR21 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20462066 | 0.75 | NOTUM (0.40) | NOTUMP2RX7PARP1PARP10PARP11 | |
| SCHEMBL21605136 | 0.75 | NOTUM (0.40) | NOTUMP2RX7PARP1PARP10PARP11 | |
| Hydrochloric Acid SCHEMBL21598427 | 0.74 | NOTUM (0.39) | NOTUMP2RX7PARP1PARP10PARP11 | |
| SCHEMBL783528 | 0.72 | FADS1 (0.46) | P2RX7 | |
| SCHEMBL783529 | 0.72 | FADS1 (0.46) | P2RX7 | |
| SCHEMBL28227757 | 0.71 | P2RX7 (0.37) | NOTUMP2RX7PARP1PARP10PARP11 | |
| SCHEMBL6583670 | 0.71 | PARP1 (0.34) | PARP1PARP10PARP11 | |
| SCHEMBL27436663 | 0.69 | ADRA1A (0.45) | — | |
| SCHEMBL257377 | 0.69 | GAA (0.45) | NOTUMP2RX7PARP1 | |
| SCHEMBL27453211 | 0.69 | NOTUM (0.39) | NOTUMP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6162818-A | 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists | THE PROCTER & GAMBLE COMPANY (US) | 2000-12-19 | — | — | US | claimed |
| EP-0944621-A1 | 2-IMIDAZOLINYLAMINOINDOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-29 | — | — | EP | claimed |
| WO-1998023610-A1 | 2-IMIDAZOLINYLAMINOINDOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1998-06-04 | — | — | WO | claimed |
| EP-0944621-B1 | 2-IMIDAZOLINYLAMINOINDOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | PROCTER & GAMBLE (US) | 2004-09-01 | — | — | EP | disclosed |
| US-6610720-B2 | Administering to the patient an alpha-2 adrenoreceptor agonist for the treatment or prevention of emesis | MERCK FROSST CANADA & CO. (CA) | 2003-08-26 | — | — | US | disclosed |
| US-6395764-B1 | NOSAL DECONGESTION, RESPIRATORY SYSTEM DISORDERS | THE PROCTER & GAMBLE COMPANY | 2002-05-28 | — | — | US | disclosed |
| US-20020045565-A1 | Method for treating or preventing emesis | MERCK FROSST CANADA LTD. (CA) | 2002-04-18 | — | — | US | disclosed |
| US-6162818-A | 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists | THE PROCTER & GAMBLE COMPANY (US) | 2000-12-19 | — | — | US | disclosed |
| EP-0944621-A1 | 2-IMIDAZOLINYLAMINOINDOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998023610-A1 | 2-IMIDAZOLINYLAMINOINDOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045565-A1 | Method for treating or preventing emesis | ADRB2, ADRA2A, ADRA2C | NOTUM 2308/4885P2RX7 902/4885PARP1 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.